Skip to main content

Advertisement

SpringerLink
Log in

Secondary effects and biochemical control in patients with early prostate cancer treated with 125-I seeds

  • Research Articles
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Objective

To retrospectively evaluate the toxicity of low-dose-rate brachytherapy and to relate it to the dose-volume to organs at risk.

Material and methods

We study 160 patients with early prostate cancer, treated with 125-I implants. Most of them were T1c (63.1%), T2a (35.6%) and Gleason ≤6 (96.2%). Median PSA was 7.2 ng/ml (2.3–13.5); 85.6% were low-risk cases and 14.4% high-risk cases. Mean follow-up was 24 months (7–48).

Results

Acute urinary toxicity related to urological quality of life (UQL=CVU) was tolerable in 75% and unsatisfactory in 25%. Urinary retention was present in 6.9%. IPSS, V100 and D90 were related to the urinary toxicity grade. Rectal toxicity (RTOG) G2 was 0.6%. Sexual potency showed no changes with regard to the basal in 69%. Actuarial biochemical control was 89.8% at four years.

Conclusions

Brachytherapy with 125-I seeds yields acceptable toxicity and excellent biochemical control.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nag S, Rodney MD, Merrick GS et al (2002) American brachytherapy society recommendations for reporting morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys 54:462–470

    Article  PubMed  Google Scholar 

  2. Blank L, Gonzalez D, Rejike TM et al (2000) Brachytherapy with transperineal 125 iodine seeds for localized prostate cancer. Radiother Oncol 57:307–313

    Article  PubMed  CAS  Google Scholar 

  3. Nag S, Beyer D, Friedland J et al (1999) American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44:789–799

    Article  PubMed  CAS  Google Scholar 

  4. Merrick GS, Butler WM, Wallner KE et al (2003) Dysuria after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 55:970–985

    Google Scholar 

  5. Ohashi T, Yorozu A, Toya K et al (2005) Acute urinary morbidity following I 125 prostate brachytherapy. Int J Clin Oncol 10:262–268

    Article  PubMed  Google Scholar 

  6. Wehle KJ, Lisson SW, Buskirk SJ et al (2004) Prediction of genitourinary tract morbidity after brachytherapy for prostate adenocarcinoma. Mayo Clin Proc 79:314–317

    Article  PubMed  Google Scholar 

  7. Gelbium DY, Potters L, Ashley R et al (1999) Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 45:59–67

    Google Scholar 

  8. Nilsson S, Norlen BJ, Widmark A (2004) A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 43:316–381

    Article  PubMed  Google Scholar 

  9. Salem N, Simonian-Sauve M, Rosello R et al (2003) Predictive factor of acute urinary morbidity after iodine-125 brachytherapy for localized prostate cancer: a phase 2 study. Radiother Oncol 66:159–165

    Article  PubMed  Google Scholar 

  10. Crook J, McLean M, Catton C et al (2002) Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 52:453–460

    PubMed  Google Scholar 

  11. Loke J, Ellis W, Wallner K et al (2002) Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachtherapy: a prospective study. Int J Radiat Oncol Biol Phys 52:712–719

    Article  Google Scholar 

  12. Bucci J, Morris WJ, Keyes M et al (2002) Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys 53:91–98

    PubMed  Google Scholar 

  13. Steineck G, Stock RG, Hong SM et al (2001) Defining the risk of developing grade 2 proctitis following 1251 prostate brachytherapy using rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 50:335–341

    Article  Google Scholar 

  14. Begg CB, Riedel ER, Bach PB et al (2002) Variations in morbidity after radical prostatectomy. N Engl J Med 346:1138–1144

    Article  PubMed  Google Scholar 

  15. Chen AB, D’Amico AV, Neville BA, Earle CC (2006) Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol 24:5298–5304

    Article  PubMed  Google Scholar 

  16. Lee N, Wuu CS, Brody R et al (2000) Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 48:1457–1460

    PubMed  CAS  Google Scholar 

  17. Keyes M, Schellenberg D, Moravan V et al (2006) Decline in urinary retention incidence in 805 patients after prostate brachytherapy: The effect of learning curve?. Int J Radiat Oncol Biol Phys 64:825–834

    PubMed  Google Scholar 

  18. Desai J, Stock RG, Stone NN et al (1998) Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Radiat Oncol Invest 6:135–141

    Article  CAS  Google Scholar 

  19. Caffo O, Fellin G, Graffer U et al (1996) Assessment of quality of life after radical radiotherapy for prostate cancer. Br J Urol 78:557–563

    PubMed  CAS  Google Scholar 

  20. Lawton CA, Won M, Pilepich MV et al (1991) Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 21:935–939

    PubMed  CAS  Google Scholar 

  21. Schultheiss TE, Lee WR, Hunt MA et al (1997) Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 37:3–11

    PubMed  CAS  Google Scholar 

  22. Carroll PR, Lee KL, Fucks ZY, Kantoff PW (2001) Cancer of the prostate. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer. Principles and practice of oncology, 6th Edn. Lippincott Williams and Wilkins, Philadelphia, PA, p 1418

    Google Scholar 

  23. Wust P, Borczyskowski DW, Henkel T et al (2004) Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy. Radiother Oncol 73:39–48

    Article  PubMed  Google Scholar 

  24. Kupelian PA, Potters L, Khuntia D et al (2004) Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≤72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-2 prostate cancer. Int J Radiat Oncol Biol Phys 58:25–33

    Article  PubMed  Google Scholar 

  25. Kang S, Chou RH, Dodge RK et al (2002) Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys 53:99–103

    PubMed  Google Scholar 

  26. Gelblum DY, Potters L (2000) Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 48:118–124

    Article  Google Scholar 

  27. Tran A, Wallner K, Merrick GS et al (2005) Rectal fistulas after prostate brachytherapy. Int J Radiat Oncol Biol Phys 63:150–154

    PubMed  Google Scholar 

  28. Wallner K, Roy J, Harrison L (1996) Tumor control and morbidity following transperineal I-125 implantation for stage T1/T2 prostate carcinoma. J Clin Oncol 14:449–453

    PubMed  CAS  Google Scholar 

  29. Waterman F, Dicker A (2003) Probability of late rectal morbidity in 125I prostate brachytherapy. Int J Radiat Oncol Biol Phys 55:342–353

    PubMed  Google Scholar 

  30. Robinson JW, Moritz S, Fung T (2002) Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 54:1063–1068

    Article  PubMed  Google Scholar 

  31. Valicenti RK, Bissonate EA, Chen C et al (2002) Longitudinal comparison of sexual function after three-dimensional conformal radiation therapy or prostate brachytherapy. J Urol 168:2499–2504

    Article  PubMed  Google Scholar 

  32. Stock RG, Stone NN, Lo YC et al (2000) Postimplant dosimetry for 125-I prostate implants: definitions and factors affecting outcome. Int J Radiat Oncol Biol Phys 48:899–906

    PubMed  CAS  Google Scholar 

  33. Merrick GS, Butler WM, Galbreath RW et al (2002) Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 52:893–902

    Article  PubMed  Google Scholar 

  34. Taussky D, Haider M, McLean M et al (2004) Factors predicting an increased dose to the penile bulb in permanent seed prostate brachytherapy. Brachytherapy 3:125–129

    Article  PubMed  Google Scholar 

  35. Potters L, Klein E, Kattan M et al (2004) Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 71:29–33

    Article  PubMed  Google Scholar 

  36. Ramos CG, Carvalhal GF, Smith DS et al (1999) Retrospective comparison of radical retropubic prostatectomy and 125 iodine brachytherapy for localized prostate cancer. J Urol 35:869–874

    Google Scholar 

  37. Quaranta BP, Marcks LB, Anscher MS (2004) Comparing radical prostatectomy and brachytherapy for localized prostate cancer. Oncology 18:1289–1302

    PubMed  Google Scholar 

  38. Beyer DC, Brachman DG (2000) Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy. Radiother Oncol 57:263–267

    Article  PubMed  CAS  Google Scholar 

  39. Guedea F, Aguilo F, Polo A et al (2006) Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1–T2 prostate cancer. Radiother Oncol 80:57–61

    Article  PubMed  CAS  Google Scholar 

  40. Lawton CA, DeSilvio M, Lee WR et al (2007) Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). Int J Radiat Oncol Biol Phys 67:39–47

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiation Oncology Department, F. Instituto Valenciano de Oncología, Valencia, Spain

    Virginia Morillo, José Luis Guinot, Isabel Tortajada, Leoncio Arribas, María Maroñas & Marian Estornell

  2. F. Instituto Valenciano de Oncología, Urology Department, Valencia, Spain

    José Vicente Ricós & Juan Casanova

Authors
  1. Virginia Morillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. José Luis Guinot
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Isabel Tortajada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. José Vicente Ricós
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Leoncio Arribas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. María Maroñas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marian Estornell
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Juan Casanova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to José Luis Guinot.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morillo, V., Guinot, J.L., Tortajada, I. et al. Secondary effects and biochemical control in patients with early prostate cancer treated with 125-I seeds. Clin Transl Oncol 10, 359–366 (2008). https://doi.org/10.1007/s12094-008-0212-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-008-0212-y

Keywords

Search

Navigation